Trial Profile
A Retrospective Study Assessing the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IxaRD) in Heavily Pretreated Patients with Multiple Myeloma in Slovenia
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 25 Jul 2018
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- 25 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.